New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 25, 2017 – Sanofi and Regeneron announced the FDA approval of a once-monthly starting dose regimen of 300 mg for Praluent (alirocumab).
Download PDF
Return to publications
